

AMENDMENTS TO THE CLAIMS

1. (CANCELED) An isolated polypeptide, wherein said polypeptide is from about 5 to about 71 amino acids in length and comprises a contiguous amino acid sequence DX_1CX_2D ; wherein X_1 and X_2 are selected from the group consisting of amino acids.

2. (CANCELED) The isolated polypeptide of claim 1, wherein X_1 is a valine or a conservatively modified variant thereof.

3. (CANCELED) The isolated polypeptide of claim 1, wherein X_2 is a glutamine or a conservatively modified variant thereof.

4. (CANCELED) The isolated polypeptide of claim 1, wherein said polypeptide comprises the contiguous amino acid sequence DVCQD.

5. (CANCELED) The isolated polypeptide of claim 1, wherein said peptide is a peptidomimetic of DX_1CX_2D , wherein X_1 and X_2 are selected from the group consisting of amino acids.

6. (CURRENTLY AMENDED) The isolated polypeptide of claim 4 11, wherein said polypeptide specifically binds to an antibody raised against Saposin B.

7. (CURRENTLY AMENDED) ~~The isolated polypeptide of claim 1, wherein said polypeptide comprises~~ An isolated polypeptide comprising an amino acid sequence substantially identical to that shown in SEQ ID NO: 1 beginning at position 7 wherein said polypeptide has antiangiogenic activity.

8. (CANCELED) The isolated polypeptide of claim 1, wherein said polypeptide comprises at least 5 contiguous amino acids, or conservatively modified variants

thereof, said contiguous amino acids having an amino acid sequence as shown in SEQ ID NO: 1, beginning at position 7.

9. (CANCELED) The isolated polypeptide of claim 1, wherein said polypeptide comprises R-DVCQD-R'; wherein R is from 0 to about 6 contiguous amino acids; and wherein R' is from 0 to about 59 contiguous amino acids.

10. (CURRENTLY AMENDED) The isolated polypeptide of claim 4 11, wherein said polypeptide is glycosylated.

11. (PREVIOUSLY PRESENTED) ~~The isolated polypeptide of claim 1,~~
~~wherein said polypeptide comprises~~ An isolated polypeptide comprising the sequence
R-XDVCQD-R', wherein:

R is selected from the group consisting of Aa₁-Aa₂-Aa₃-Aa₄-Aa₅, Aa₂-Aa₃-Aa₄-Aa₅, Aa₃-Aa₄-Aa₅, Aa₄-Aa₅, and Aa₅ and non-existent, that is, the sequence is XDVCQDR', and wherein:

Aa₁ is glutamine, a conservative substitution thereof, or, if one or more of Aa₂, Aa₃, Aa₄ and Aa₅ is a specific amino acid indicated herein, any amino acid;

Aa₂ is proline, a conservative substitution thereof, or, if one or more of Aa₁, Aa₃, Aa₄ and Aa₅ is a specific amino acid as indicated herein, any amino acid;

Aa₃ is lysine, a conservative substitution thereof, or, if one or more of Aa₁, Aa₂, Aa₄ and Aa₅ is a specific amino acid indicated herein, any amino acid;

Aa₄ is aspartic acid, a conservative substitution thereof, or, if one or more of Aa₁, Aa₂, Aa₃ and Aa₅ is a specific amino acid as indicated herein, any amino acid;

Aa₅ is asparagine, a conservative substitution thereof, or, if one or more of Aa₁, Aa₂, Aa₃ or Aa₄ is a specific amino acid as indicated herein, any amino acid; and,

X is selected from the group consisting of ~~G, A, S and T~~ glycine, alanine, serine and threonine; and, ~~wherein~~

R' is from 0 to about 59 contiguous amino acids.

12. (CANCELED) The isolated polypeptide of claim 11, wherein Aa₁, is a glutamine or a conservative substitution thereof.

13. (CANCELED) The isolated polypeptide of claim 11, wherein Aa₂ is a proline or a conservative substitution thereof.

14. (CANCELED) The isolated polypeptide of claim 11, wherein Aa₃ is a lysine or a conservative substitution thereof.

15. (CANCELED) The isolated polypeptide of claim 11, wherein Aa₄ is an aspartic acid or a conservative substitution thereof.

16. (CANCELED) The isolated polypeptide of claim 11, wherein Aa₅ is a asparagine or a conservative substitution thereof.

17. (PREVIOUSLY PRESENTED) The isolated polypeptide of claim 11, wherein R' is selected from the group consisting of Aa₁₂-Aa₁₃-Aa₁₄-Aa₁₅-Aa₁₆, Aa₁₂-Aa₁₃-Aa₁₄-Aa₁₅, Aa₁₂-Aa₁₃-Aa₁₄, Aa₁₂-Aa₁₃ and Aa₁₂, wherein Aa₁₂, Aa₁₃, Aa₁₄, Aa₁₅ and Aa₁₆ are selected from the group consisting of amino acids.

18. (PREVIOUSLY PRESENTED) The isolated polypeptide of claim 17, wherein Aa₁₂ is a cysteine or a conservative substitution thereof

19. (PREVIOUSLY PRESENTED) The isolated polypeptide of claim 17, wherein Aa₁₃ is an isoleucine or a conservative substitution thereof.

20. (PREVIOUSLY PRESENTED) The isolated polypeptide of claim 17 wherein Aa₁₄ is an glutamine or a conservative substitution thereof.

21. (PREVIOUSLY PRESENTED) The isolated polypeptide of claim 17, wherein Aa₁₅ is an methionine or a conservative substitution thereof.

22. (PREVIOUSLY PRESENTED) The isolated polypeptide of claim 17, wherein Aa₁₆ is a valine or a conservative substitution thereof

23. (CURRENTLY AMENDED) The isolated polypeptide of claim + 11, which has the amino acid sequence GDVCQDCIQMV.

24. (WITHDRAWN) An isolated protein, wherein said protein specifically binds to Saposin B and is found on the surface of cells selected from the group consisting of KS Y-1, SLK and HUVEC

25. (WITHDRAWN) The isolated protein of claim 24, wherein said protein is recombinantly expressed.

26. (WITHDRAWN) An antibody that is specifically reactive with the isolated polypeptide of claim 1.

27. (WITHDRAWN) The antibody of claim 26, wherein said monoclonal antibody is a monoclonal antibody.

28. (WITHDRAWN) The antibody of claim 26, wherein said antibody is a single chain antibody.

29. (CURRENTLY AMENDED) A method of treating a mammal, wherein said ~~organism~~ mammal has a pathological condition associated ~~to~~ with undesired angiogenesis, by administering an amount of ~~an~~ the isolated polypeptide of claim 11 ~~comprising a contiguous amino acid sequence DX₁CX₂D, wherein X₁ and X₂ are selected from the group consisting of amino acids, and, said polypeptide has antiangiogenic activity, and~~ wherein said amount of polypeptide is effective to reduce angiogenesis.

30. (PREVIOUSLY PRESENTED) The method of claim 29, wherein the mammal is human.

31. (PREVIOUSLY PRESENTED) The method of claim 29, wherein said pathological condition is cancer.

32. (PREVIOUSLY PRESENTED) The method of claim 31, wherein said cancer is Kaposi's Sarcoma.

33. (PREVIOUSLY PRESENTED) The method of claim 29, wherein administration is selected from the group consisting of subcutaneous, intramuscular, intravenous, intra-arterial, intrabronchial, oral, transdermal, intraocular, rectal, vaginal, intranasal, sublingual and intralesional.

34. (PREVIOUSLY PRESENTED) The method of claim 33, wherein the administration is selected from the group consisting of intralesional and transdermal.

35. (CANCELED) The method of claim 29, wherein said isolated polypeptide is Saposin B.

36. (PREVIOUSLY PRESENTED) The method of claim 29, wherein said therapeutic amount is from about 0.1 mg/kg to about 20 mg/kg.

37. (CURRENTLY AMENDED) A pharmaceutical composition in unit dosage form, ~~which comprises~~ comprising:

- (a) one or more pharmaceutically acceptable excipients, and
- (b) an amount of ~~a the isolated~~ polypeptide of claim 11, ~~comprising a contiguous amino acid sequence DX₁CX₂D, wherein X₁ and X₂ are selected from the group consisting of amino acids; and~~ wherein the polypeptide is effective to treat or prevent undesired angiogenesis in an animal or patient to whom one or more unit doses of said composition are administered.

38. (PREVIOUSLY PRESENTED) The pharmaceutical composition of claim 37, wherein said unit dosage form is an aseptic solution comprising said polypeptide.

39. (CURRENTLY AMENDED) The pharmaceutical composition of claim 37, wherein said unit dosage form is a topical ointment comprising said polypeptide.

40. (CURRENTLY AMENDED) An isolated fusion protein, said fusion protein comprising ~~a the isolated polypeptide of claim 11 a contiguous amino acid sequence DX₁CX₂D, wherein X₁ and X₂ are selected from the group consisting of amino acids,~~ and a cell targeting moiety; wherein said cell targeting moiety and said polypeptide have functional activity independent of each other.

41. (PREVIOUSLY PRESENTED) The isolated fusion protein of claim 40, wherein said cell targeting moiety is a protein.

42. (CURRENTLY AMENDED) The isolated fusion protein of claim ~~40~~ 41, wherein said protein is an antibody.

43. (PREVIOUSLY PRESENTED) The isolated fusion protein of claim 42, wherein said antibody is a monoclonal antibody.

44. (PREVIOUSLY PRESENTED) The isolated fusion protein of claim 43, wherein said antibody is a single chain Fv antibody.

45. (CURRENTLY AMENDED) An isolated fusion protein, said fusion protein comprising a the isolated polypeptide of claim 11 ~~a contiguous amino acid sequence DX₁CX₂D, wherein X₁ and X₂ are selected from the group consisting of amino acids and a cytotoxic moiety; wherein said cell-targeting cytotoxic moiety and said polypeptide~~ have functional activity independent of each other.

46. (PREVIOUSLY PRESENTED) The isolated fusion protein of claim 45, wherein said cytotoxic moiety is a protein.

47. (CURRENTLY AMENDED) The isolated fusion protein of claim 45 46, wherein said protein is a bacterial toxin.

48. (CURRENTLY AMENDED) The isolated fusion protein of claim 47, wherein said bacterial toxin is ~~from~~ Diphtheria toxin.

49. (CURRENTLY AMENDED) The isolated fusion protein of claim 48, wherein said ~~bacterial~~ Diphtheria toxin is the B chain of ~~Diphtheria~~ Diphtheria toxin,

50. (CANCELED) The isolated fusion protein of claim 47, wherein said bacterial toxin is from Pseudomonas.

51. (CURRENTLY AMENDED) The isolated fusion protein of claim ~~50~~ 47, wherein said bacterial toxin is Pseudomonas exotoxin.

52. (PREVIOUSLY PRESENTED) The isolated fusion protein of claim 51, wherein said *Pseudomonas* exotoxin is selected from the group consisting of PE38 and PE40.